Try our beta test site

Cetuximab in Treating Patients With Advanced Solid Tumors

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
University of California, Davis Identifier:
First received: September 13, 2006
Last updated: March 25, 2010
Last verified: March 2010

RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.

PURPOSE: This phase I trial is studying the side effects and best dose of cetuximab in treating patients with advanced solid tumors.

Condition Intervention Phase
Unspecified Adult Solid Tumor, Protocol Specific
Biological: cetuximab
Genetic: molecular diagnostic method
Other: immunologic technique
Other: laboratory biomarker analysis
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Study of the Safety and Tolerability of Four Doses of Cetuximab (C225) in Patients With Advanced Solid Tumors

Resource links provided by NLM:

Further study details as provided by University of California, Davis:

Primary Outcome Measures:
  • Maximum tolerated dose of cetuximab [ Time Frame: December 2007 ]

Secondary Outcome Measures:
  • Safety and tolerability of cetuximab [ Time Frame: December 2007 ]
  • Potential predictors of response using correlative studies [ Time Frame: December 2007 ]
  • Correlation of efficacy of cetuximab with grade of skin rash [ Time Frame: December 2007 ]
  • Development of a detailed scale for assessing skin rash [ Time Frame: December 2007 ]

Enrollment: 27
Study Start Date: December 2004
Study Completion Date: December 2007
Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Phase I dose escalation study Biological: cetuximab
Dose level 0: cetuximab 400 mg/m2 week 1, 250 mg/m2 weekly; Dose level 1: cetuximab 400 mg/m2 week 1, 300 mg/m2 weekly; Dose level 2: cetuximab 400 mg/m2 week 1, 350 mg/m2 weekly; Dose level 3: cetuximab 400 mg/m2 week 1, 400 mg/m2 weekly
Other Names:
  • IMC-C225
  • Erbitux
Genetic: molecular diagnostic method
Tissue and Blood Specimens; IHC Methodology; IHC Scoring; K-RAS Mutation Analysis
Other: immunologic technique
Peripheral Blood Mononuclear Cells (PBMC)
Other: laboratory biomarker analysis
Cetuximab Pharmacodynamics

Detailed Description:



  • Determine the maximum tolerated dose of cetuximab in patients with advanced solid tumors.


  • Evaluate the safety and tolerability of this drug in these patients.
  • Develop a detailed scale for assessment of rash in these patients.
  • Investigate potential predictors of response using correlative studies on patient tissue, buccal mucosa, and blood samples.
  • Obtain preliminary efficacy data and evaluate the relationship of efficacy to grade of rash.
  • Correlate downstream markers (e.g., pMAPK, pAKT, and Ki-67) and the presence of epidermal growth factor receptor (EGFR) polymorphisms with clinical response and/or survival.
  • Examine the levels of downstream marker proteins in buccal cells obtained pre- and post-treatment.
  • Correlate basal p27 expression levels with response and/or survival.
  • Determine if the presence of a K-RAS mutation influences response or survival outcome.
  • Correlate the presence or absence of mutant K-RAS tumor DNA shed into patient plasma with response and/or outcome.
  • Correlate levels of cytokines and chemokines with rash and clinical response.

OUTLINE: This is an open-label, dose-escalation study.

Patients receive cetuximab IV over 90 minutes once weekly for 4 weeks. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of cetuximab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.

Patients undergo blood and buccal mucosa collection at baseline and prior to courses 2 and 3 of treatment for molecular correlative studies. Archival tumor tissue specimens are also used for molecular correlative studies. Immunologic correlative studies are performed using patient blood samples.

After completion of study treatment, patients are followed periodically for survival.

PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed written informed consent
  • Histologically or cytologically proven advanced solid tumors not curable by surgery, radiation therapy or standard chemo-, immuno-, or hormonal therapy. A specific primary cancer need not have been identified (i.e., unknown primary is eligible).
  • Patients must have received at least one prior regimen (chemotherapy and/or radiation) for metastatic disease. There is no limit to the number of prior therapies.
  • Any prior chemotherapy must have been completed at least 4 weeks prior to start of study therapy. Previous radiation therapy must have been completed at least 2 weeks prior to start of study therapy. All side effects of prior therapy must be resolved prior to the start of study therapy.
  • Patients with ZUBROD performance status 0-2 (see Appendix 1).
  • Patients must have measurable disease or evaluable disease.
  • Patients must have an estimated survival of at least 3 months.
  • Patients with asymptomatic treated brain metastasis (surgical resection or radiotherapy) may be included if they are neurologically stable and have been off steroids for at least 4 weeks.
  • Patients >/= 18 years of age.
  • Patients of reproductive potential must agree to use an effective contraceptive method while on treatment and for 3 months afterward as the effects of cetuximab on the unborn fetus are unknown.
  • Patients must have adequate hematologic function defined as: ANC >/= 1,500/mm3, platelets >/= 100,000/mm3.
  • Patients must have adequate hepatic function defined as SGOT </= 3 x institutional UNL and serum bilirubin </= 2.0 mg/dL.
  • Patients must have adequate renal function defined as a serum creatinine level </= 1.6 mg/dL or a calculated creatinine clearance of >/= 40 ml/min.

Exclusion Criteria:

  • Female patients cannot be pregnant or breastfeeding as the effects of cetuximab on the unborn fetus are unknown. Documentation of a negative pregnancy test prior to treatment is required for all women of reproductive potential.
  • Uncontrolled intercurrent illness including but not limited to ongoing infection or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements.
  • Patients with symptomatic brain metastasis or still requiring steroids.
  • Patients who have received prior cetuximab therapy, prior therapy with any other drug that targets the EGF receptor (including, but not limited to, Iressa, Tarceva, Herceptin, CI1033, etc.), or prior therapy with a monoclonal antibody.
  • Patients who have received prior chemotherapy within 4 weeks or radiation therapy within 2 weeks prior to the start of study therapy.
  • Prior hypersensitivity reaction to chimerized or murine monoclonal antibody therapy.
  • Patients may not receive any other chemotherapy, radiation therapy, or biologic therapy while on study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00376727

United States, California
University of California Davis Cancer Center
Sacramento, California, United States, 95817
Sponsors and Collaborators
University of California, Davis
National Cancer Institute (NCI)
Study Chair: Angela Davies, MD University of California, Davis
  More Information

Responsible Party: Angela Davies, MD, University of California, Davis Identifier: NCT00376727     History of Changes
Other Study ID Numbers: CDR0000506089
P30CA093373 ( US NIH Grant/Contract Award Number )
UCDCC-165 ( Other Identifier: University of California, Davis - Cancer Center )
BMS-CA225027 ( Other Grant/Funding Number: Bristol-Myers Squibb )
200412499 ( Other Identifier: University of California, Davis - IRB )
IMCL-8420 ( Other Grant/Funding Number: Imclone Systems, Inc. )
Study First Received: September 13, 2006
Last Updated: March 25, 2010

Keywords provided by University of California, Davis:
unspecified adult solid tumor, protocol specific

Additional relevant MeSH terms:
Antineoplastic Agents processed this record on March 27, 2017